Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)

NEW YORK, NY - (NewMediaWire) - October 03, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are a Shattuck investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.

Headquartered in Austin, Texas, Shattuck operates as a clinical-stage biotechnology company, focusing on the development of biologic medicines for the treatment of cancer and autoimmune diseases.

On October 1, 2024, Shattuck disclosed in an 8-K filing with the Securities and Exchange Commission that they would be discontinuing their trial for SL-172154, a drug candidate in the treatment of Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.  The Company also disclosed they would be cutting its staff by 40% and that a potentially lucrative license agreement with a Japanese pharmaceutical company would be terminated.

Following this news, Shattuck stock price fell $1.57 per share, nearly 45%, to close at $1.92 per share on October 1, 2024.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

Jeffrey P. Campisi

KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571

jcampisi@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com